efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
Clicks: 164
ID: 141333
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
164 views
37 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #20 of 44 articles by views in jurnal pengajaran mipa
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Naila Goldenberg1,2, Charles Glueck11Cholesterol and Metabolism Center of Jewish Hospital, Cincinnati, Ohio, USA; 2University of Cincinnati, Division of Endocrinology and Metabolism, Cincinnati, Ohio, USAAbstract: Statins became available for the treatment of hypercholesterolemia in 1987. Multiple, well-designed, placebo-controlled, double-blind studies revealed that each 1% reduction in serum cholesterol level was associated with about 1% reduction in risk of cardiovascular events. Low-density lipoprotein (LDL) cholesterol reduction to less than 78 mg/dL may be associated with reduction of atheroma burden. Patients with high levels of high specificity C-reactive protein and having LDL cholesterol less than 3.4 mmol/L (130 mg/dL) in primary prevention settings benefited from aggressive LDL cholesterol reduction with rosuvastatin over a 2-year period. However, in real life practice, about half of patients who are prescribed statins discontinue the medication by the end of the year. Medication adherence is lower in younger patients, women, and absence of known coronary heart disease. Personal features of the prescribing physician and dispensing pharmacies also affect patients’ compliance. More studies are needed to evaluate if “compliance packets” would benefit patients in a real life situation.Keywords: cardiovascular risk, statin, goal attainment, primary prevention, secondary prevention
| Reference Key |
goldenberg2009vascularefficacy,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Naila Goldenberg;Charles Glueck |
| Journal | jurnal pengajaran mipa |
| Year | 2009 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.